TRT should begin with diagnosis, not marketing. Major clinical guidance recommends diagnosing hypogonadism only when compatible symptoms are present and testosterone is consistently low on properly obtained testing.
What counts as a responsible evaluation?
- Review symptoms, medical history, sleep, medications, alcohol, body composition, and recent illness.
- Measure morning fasting total testosterone with a reliable assay.
- Repeat a low result on a separate morning.
- Use additional testing when appropriate to understand the cause or clarify borderline results.
Low energy, reduced libido, erectile changes, lower strength, low mood, and poor concentration can occur with low testosterone—but also with sleep apnea, depression, thyroid problems, medication effects, calorie restriction, chronic disease, and inadequate recovery.
What may improve?
In men with confirmed hypogonadism, treatment may improve sexual symptoms, body composition, anemia, and some measures of bone health. Results vary. TRT does not replace resistance training, nutrition, sleep, or management of cardiometabolic risk.
The monitoring conversation
| Area | Why it matters |
|---|---|
| Symptoms and testosterone | Confirm benefit and avoid unnecessary exposure |
| Hematocrit | TRT can raise red-cell concentration |
| Blood pressure | FDA now requires class-wide warnings about increases |
| Prostate assessment | Shared decision-making based on age and risk |
| Sleep apnea symptoms | Untreated severe apnea requires attention |
| Fertility | Exogenous testosterone can suppress sperm production |
What changed in the cardiovascular discussion?
The large TRAVERSE trial found testosterone therapy was noninferior to placebo for major adverse cardiac events in the studied population: middle-aged and older men with symptoms, repeatedly low testosterone, and existing or high cardiovascular risk. That does not mean TRT prevents heart disease or is risk-free for every patient.
In 2025, the FDA removed prior boxed-warning language about increased adverse cardiovascular outcomes after reviewing TRAVERSE, while requiring warnings about increased blood pressure across testosterone products. The FDA also retained the limitation of use for age-related low testosterone.
Who should pause before treatment?
Clinical guidance identifies important contraindications or reasons for specialist evaluation, including plans for near-term fertility, certain prostate or breast cancers, markedly elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, recent myocardial infarction or stroke, and thrombophilia.
The Biohack Journey verdict
TRT is medical treatment for a defined condition—not a general anti-aging supplement. A good program uses symptoms, repeat measurements, cause evaluation, conservative goals, and ongoing monitoring.